Selecta Biosciences (SELB) Phase 1/2 Clinical Trial of SEL-302 for the Treatment of Methylmalonic Acidemia Placed on Clinical Hold

Go back to Selecta Biosciences (SELB) Phase 1/2 Clinical Trial of SEL-302 for the Treatment of Methylmalonic Acidemia Placed on Clinical Hold

Selecta Biosciences (SELB) to Resume Trading at 4:45 p.m.

November 24, 2021 4:21 PM EST

Selecta Biosciences (NASDAQ: SELB) to Resume Trading at 4:45 p.m.

... More